Drug
Saroglitazar
Saroglitazar: highest development phase Post-Market, developed by Zydus. 17 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Zydus
Trials
| Drug | Phase | Indication |
|---|---|---|
| Saroglitazar NCT05872269 | Post-Market | NAFLD |
| Saroglitazar Magnesium 1 mg NCT07424677 | Phase 3 | Primary Biliary Cholangitis |
| Saroglitazar magnesium 1 mg NCT07216235 | Phase 3 | Primary Biliary Cholangitis |
| Saroglitazar Magnesium 1 mg NCT06427395 | Phase 3 | Primary Biliary Cholangitis |
| Saroglitazar Magnesium 1 mg NCT05133336 | Phase 2/3 | Primary Biliary Cholangitis |
| Saroglitazar NCT03639623 | Phase 2 | Liver Transplant; Complications |
| Saroglitazar magnesium 2 mg NCT03112681 | Phase 2 | Primary Biliary Cirrhosis |
| Saroglitazar Magnesium 2 mg NCT05011305 | Phase 2 | Nonalcoholic Steatohepatitis |
| Saroglitazar Magnesium 4 mg Tablet NCT03617263 | Phase 2 | Non-alcoholic Fatty Liver Disease in Women With PCOS |
| Saroglitazar Magnesium 4 mg NCT05211284 | Phase 2 | Nonalcoholic Fatty Liver Disease |
| Saroglitazar magnesium 1 mg NCT03061721 | Phase 2 | Non-Alcoholic Fatty Liver Disease |
| Saroglitazar Magnesium 2mg NCT03863574 | Phase 2 | Non Alcoholic Steatohepatitis |
| Saroglitazar Magnesium 2 mg NCT04469920 | Phase 1 | Hepatic Impairment |
| Saroglitazar Magnesium 1 mg NCT05045482 | Phase 1 | Hepatic Impairment |
| Saroglitazar magnesium 4mg NCT04045769 | Phase 1 | Healthy |
| Saroglitazar magnesium NCT04446507 | Phase 1 | Renal Impairment |
| Saroglitazar Magnesium 1 mg NCT06825559 | Phase 1 | Cholestatic Liver Disease |
Latest
No recent events.
Follow Saroglitazar on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.